Kelsey Stephen Michael 4
4 · Revolution Medicines, Inc. · Filed Sep 15, 2025
Insider Transaction Report
Form 4
Kelsey Stephen Michael
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-09-11$4.73/sh+100,000$473,000→ 389,414 total - Sale
Common Stock
2025-09-15$45.92/sh−23,682$1,087,418→ 290,732 total - Sale
Common Stock
2025-09-15$46.93/sh−1,318$61,854→ 289,414 total - Exercise/Conversion
Common Stock
2025-09-15$4.73/sh+25,000$118,250→ 314,414 total - Sale
Common Stock
2025-09-11$43.58/sh−44,059$1,919,963→ 345,355 total - Sale
Common Stock
2025-09-11$44.48/sh−55,941$2,488,519→ 289,414 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-11−100,000→ 55,055 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (100,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-15−25,000→ 30,055 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (25,000 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
- [F2]Includes 94,426 restricted stock units.
- [F3]The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.